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Endoscopic ultrasound (EUS) is the most sensitive imaging modality for solid pancreatic lesions. The speciﬁcity, however, is low
(about 75%). It can be increased to 100% with an accuracy of 95% by the addition of ﬁne-needle aspiration (FNA). Cytopathology
playsanimportantrole.Theﬁnaldiagnosisisbaseduponthecorrelationofclinical,EUS,andcytologicfeatures.Acloseinteraction
with the cytopathologist is required in improving the diagnostic yield. In this paper, we present an overview of the role of EUS-
guided FNA and importance of close interaction with the cytopathologist. Day to day examples of diﬀerent solid pancreatic lesions
have been presented at the end.
1.Introduction
Endoscopic ultrasound (EUS) is an emerging imaging mo-
dality. EUS-guided ﬁne-needle aspiration (FNA) plays an
important role in solid pancreatic lesions. A close interaction
with cytopathology is vital in improving the diagnostic yield.
The ﬁnal diagnosis is based upon correlation of clinical,
EUS, and cytologic features. In this paper, we will discuss
the role of EUS-FNA, and the importance of cytopathology
in the diagnosis of solid pancreatic lesions. We will describe
the history and safety of EUS, indications for an EUS-
FNA, and a short description of the technique of EUS-FNA.
We will also discuss the importance of arranging an onsite
cytopathologist and alternatives if that is not feasible. Finally,
we will present the clinical, EUS, and key cytologic features
of a few representative solid pancreatic lesions.
2.Endoscopic Ultrasound(EUS):Background
Endoscopic ultrasound (EUS) was ﬁrst introduced by Dr.
Eugene DiMagno in the 1980s by combining a high-
frequency ultrasound transducer to an endoscope [1]. Initial
echoendoscopes were radial, which scan perpendicular to
scope’s axis and provide 360-degree images similar to
computerized tomography (CT) (Figure 1). In 1991, convex
linear-array echoendoscope was introduced by Pentax (FG-
32). These linear scopes scan parallel to the longitudinal axis
of the scope and enable ﬁne needle aspiration (FNA) and
diﬀerent therapeutic applications (Figure 2).
Diﬀerent imaging modalities are available to help diag-
nosesolidpancreaticlesionsincludingtransabdominalultra-
sound, computerized tomography (CT), magnetic resonance
imaging (MRI), endoscopic retrograde cholangiopancre-
atography (ERCP), EUS, and positron emission tomography
(PET). EUS is considered one of the most sensitive imaging
modalities to detect pancreatic masses, with an accuracy of
78–94% for T (local tumor) stage and 64–82% for N (lymph
node) stage [2–4]. EUS is an outpatient procedure and can
be done under conscious sedation, like a standard upper
endoscopy. The pancreas is imaged from the stomach and
duodenum.
Overall, EUS is a safe procedure with most of the com-
plications related only to FNA. The complications include
bleeding (0–1.3%) [5–7], perforation 0–0.4% [5, 6], infec-
tion (0.3%) [5, 6], and pancreatitis (1-2%) [5]. The risk of
bacteremia is low, and prophylactic antibiotics are not rec-
ommended except for EUS-FNA of pancreatic cystic lesions
[8]. The risk of tumor seeding is signiﬁcantly lower as
compared to percutaneous approach [9] with only four
case reports so far. The risk of tumor seeding is further2 Pathology Research International
Figure 1: Radial echoendoscope. The tip of the scope scans
perpendicular to its axis, providing 360-degree view.
Figure 2: Linear echoendoscope. The tip scans parallel to its
longitudinal axis. An FNA needle is seen coming out of the scope
channel.
diminished due to the inclusion of needle tract in the resec-
tion ﬁeld of pancreatic head lesions.
3.EUS-GuidedFineNeedle
Aspiration (EUS-FNA): Indications,
Accuracy, andTechnique
Although EUS is a very sensitive imaging modality, its ability
to diﬀerentiate benign inﬂammatory and malignant pancre-
atic masses is low. The speciﬁcity is only about 75% [10].
The speciﬁcity can be increased to 100% with FNA with an
accuracy of 95% [11]. However, the negative predictive value
ofEUS-FNAislow(56%)[12],andanegativeresultdoesnot
completely exclude malignancy. Hence, the need for routine
EUS-FNA of potentially resectable pancreatic mass lesions
noted on other imaging modalities is controversial [13]. In a
review article by Varadarajulu and Eloubeidi [14], EUS-FNA
was indicated in the following cases.
(1) Unresectable mass as a prerequisite for adjuvant
chemotherapy or radiation.
(2) Suspected other tumor types like lymphoma, small
cell metastasis, or neuroendocrine tumors that re-
quire diﬀerent therapy.
(3) When the pretest probability of malignancy is low.
(a)
(b)
Figure 3: EUS-FNA needle. (a) The handle of the FNA needle is
shown with a stylet inside and a suction syringe. (b) The tip of the
FNA needle used for puncturing the tissue is shown.
(4) Patient refuses major surgery without a deﬁnitive di-
agnosis.
EUS-FNAisdoneunderreal-timeEUSimaging[15].The
needle device is inserted into the biopsy channel of the linear
echoendoscope. The stylet is withdrawn a few millimeters to
expose the sharp tip of the needle, followed by advancement
of the tip into the target lesion (Figure 3). Doppler is used to
avoid any vessels. Once the needle is inside the target tissue,
the stylet is ﬁrst pushed in to expel any needle tract tissue
and then removed out of the needle. Suction is applied by
attaching a 10–20mL syringe. The needle is moved to and
fro about 10–20 times in a fanlike pattern inside the lesion.
The suction syringe is released, the needle is withdrawn
into the catheter, and the whole device is removed from
the echoendoscope. The material is sprayed onto glass slides
by using either air-ﬁlled syringe or the stylet, with half of
the material ﬁxed in ethanol (for Papanicolaou staining)
and the remainder air-dried for onsite cytologic evaluation
using Diﬀ-Quik staining (Figure 4). Material for cell block
is then obtained by recovering tissue fragments or clot from
slides and also rinsing the EUS needle with sterile saline.
Pancreatic adenocarcinoma and lymph node metastases of
known origin can be usually diagnosed with smears alone.
However with suspected neuroendocrine tumor, metastasis
of unknown primary, mesenchymal neoplasms, lymphopro-
liferative disorders, or any other unusual case, suﬃcient
material is needed in cell block for immunocytochemistry
[16]. With suspected lymphoma, a separate sample in
Roswell Park Memorial Institute (RPMI) solution is pre-
ferred for ﬂow cytometry [17].Pathology Research International 3
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Figure 4: Diﬀ-Quik staining method. Air-dried smears are stained
in three steps and takes about 10–20 seconds each. The smear is ﬁrst
ﬁxed in methyl alcohol solution, followed by staining with solution
I containing L-xanthene (an eosin variant), and then solution II
containingmethyleneblueandazureA.Theslideisthenrinsedwith
water and the wet slide is viewed under the microscope.
4.DiagnosticYieldof EUS-FNA andthe
Importance of anOnsite Cytopathologist
The diagnostic yield of EUS-FNA for solid pancreatic lesion
is 86.8–98.5% for cytologic and 68.9–89% for histologic
examinations, while 65–100% for lymph nodes [18]. How-
ever, there are certain variables that can aﬀect the accuracy
and diagnostic yield of EUS-FNA. These can be categorized
as either endoscopist or cytopathologist related.
The success rate of EUS-FNA increases with endosco-
pist experience. The American Society of Gastrointestinal
Endoscopy(ASGE)hasrecommendedatleast150supervised
EUS procedures, including 50 EUS-FNAs (of which half
are pancreatic and another half nonpancreatic) to achieve
comprehensive competency [19]. Getting the target lesion
in good view, selecting proper needle size, and proper FNA
techniqueareassociatedwithincreaseddiagnostic yield[20].
The available needles are 25, 22, and 19 gauges. For solid
pancreatic lesions, the 25-gauge needle is at least equivalent
[21–24] or even superior for cytological diagnosis [25, 26]
dueto lessblood contamination as comparedto the standard
22-gauge needle. However, certain tumors such as malignant
lymphomas, rare pancreatic neoplasms, well-diﬀerentiated
adenocarcinoma, mesenchymal tumors, as well as benign
conditions,suchasautoimmunepancreatitismaybediﬃcult
to diagnose based on cytology alone. In such cases, core
biopsies can be obtained using 22- or 19-gauge aspiration
needles [27]. A spring-loaded 19-gauge Tru-Cut needle is
also available for histologic diagnosis. However, it is diﬃcult
to deploy especially for pancreatic head lesions [28].
The diagnostic success of EUS-FNA also depends on
the cytopathologist’s experience. Unlike percutaneous biop-
sies, EUS-FNA material is contaminated by gastrointestinal
epithelium [29, 30] leading to errors in diagnosis. It is im-
portant for the cytopathologist to be aware of the route
traversed by the needle for proper evaluation of the smears.
Training courses are required for cytopathologist with no
previous experience with EUS-FNA [31, 32]. Proper han-
dlingandtriagingofEUS-FNAmaterialfollowingimmediate
onsite cytologic evaluation are very helpful [33]. Immediate
cytologic evaluation not only improves the diagnostic yield,
but can potentially reduce the number of needle passes, pro-
cedure time, and patient risk [34]. However, it is expensive
and many of the centers may not have an onsite cytopathol-
ogist. In a study by Savoy et al. [35], even experienced
endosonographers were less reliable than cytotechnologists
in evaluating onsite adequacy macroscopically. When either
anonsitecytopathologistorcytotechnologistisnotavailable,
options are to use multiple needle passes or telecytopathol-
ogy.
The optimal number of EUS FNA needle passes range
from two to six [36]. In study by Erickson et al. [34]w h e r e
onsite cytopathologist was not available, 5-6 passes were
needed for diagnosis of pancreatic masses and 2-3 for liver
metastasesandlymphnodes.Howeverinanotherstudy[36],
at least 7 passes were needed for pancreatic and miscellane-
ousmasses(includingmediastinal,perirectal,andsubepithe-
lial) and 5 passes into lymph nodes for correct diagnosis. In
a retrospective multicenter study [37], gross or macroscopic
assessment of the specimen for adequacy by the endosonog-
rapher (“one or more small-core biopsy cylinders”) resulted
in limitation of the number of needle passes to only 1-2 in
92% of the patients with solid pancreatic lesions. However,
the macroscopic assessment was wrong in 13.5% of the
cases due to presence of ﬁbrous tissue, gastrointestinal con-
tamination, or occasionally clot. However in another study
[38], neither endosonographers nor cytotechnologists were
able to provide a reliable assessment of FNA adequacy for
solid pancreatic lesions by using gross visual inspection
of the specimen on a slide. Another emerging concept is
telecytopathology which may be a valid substitute to onsite
cytopathologic evaluation. The slides are initially prepared
and prescreened by a cytotechnologist or pathology resident
a n dt h e na n a l y z e db ya no ﬀsite cytopathologist using real-
time remotely operated system (MedMicro System; Trestle
Corporation of Irvine, CA). In a retrospective study [39],
telecytopathology was statistically equivalent in accuracy to
onsite cytopathologist for pancreatic carcinoma.
5. EUS andCytologicFeaturesof Different
PancreaticSolidLesions
The clinical and radiological ﬁndings should correlate with
the FNA results on whether the pancreatic lesion is benign
or malignant [40]. It is the composite picture of cell type,
microarchitecture, and nuclear and cytoplasmic features that
determine the cytologic diagnosis. The smear is ﬁrst exam-
ined under low magniﬁcation for cellularity, cell types, and
cohesiveness,followedbyhigh-magniﬁcationexaminationof
nuclear and cytoplasmic features. Speciﬁc nuclear features
determine malignancy, whereas cytoplasmic features and
microarchitecture determine diﬀerentiation. Malignant cells
exhibit disorganization and discohesion (loosely aggregated4 Pathology Research International
(a) (b)
Figure 5: Pancreatic ductal adenocarcinoma. (a) EUS showed a 17mm by 15mm hypoechoic and homogenous solid mass in the pancreatic
head area obstructing the distal common bile duct (CBD) and main pancreatic duct (PD) near ampulla. (b) A single FNA was done using
25-gauge needle via transduodenal approach.
or single cells). Nuclear features of malignant cells include
enlarged nuclei (higher nuclear to cytoplasmic ratio), vari-
ation in nuclear size and shape from cell to cell (anisonu-
cleosis), hyperchromasia (increase amount of chromatin),
multiple or irregular nucleoli, and abnormal mitotic ﬁgures.
Cytoplasmicfeatures(mucininadenocarcinomaandﬁnered
granules in neuroendocrine tumors) and microarchitecture
(glands or papillae) help classify the tumor. In poorly diﬀer-
entiated or metastatic lesions, immunohistochemical stain-
ing of the cell blocks may be needed to determine the origin.
6. Examplesof DifferentSolid
PancreaticLesions
Next, we will discuss the clinical, EUS, and cytologic features
of diﬀerent solid pancreatic lesions.
(1) Pancreatic ductal adenocarcinoma: a 67-year-old
gentleman presented with painless jaundice. MRI abdomen
showed dilated bile and pancreatic ducts, but no obvious
pancreatic mass was noted. EUS showed a 17mm by 15mm
hypoechoic and homogenous mass in the pancreatic head
area obstructing the distal common bile duct (CBD) and
main pancreatic duct (PD) near ampulla (Figure 5). One
FNA was done using 25-gauge needle via transduodenal
approach. The specimen was analyzed by an onsite cytopa-
thologist for adequate cellularity.
Onsite evaluation for a poorly diﬀerentiated adenocarci-
noma is relatively easy because of increased cellularity and
markedly atypical clusters with a 3-dimensional appearance
(Figure 6). Necrosis may be evident in the background. On
the other hand, a well-diﬀerentiated adenocarcinoma can
be challenging even on alcohol ﬁxed and Papanicolaou-
stained smears. The key is to establish at least one completely
normal ductal epithelium which would have uniformly
sized, bland nuclei, equidistant from each other, giving
it a honeycombed appearance (Figure 7). All other cell
groups are compared to this normal standard. In a well-
diﬀerentiated adenocarcinoma, the four most outstanding
diﬀerences from normal epithelium are overall larger nuclei
as compared to normal; nuclear size variation such that the
largest nucleus in the group may be three times the smallest
nucleus; unequal spacing of nuclei resulting in a loss of
polarity, also referred to as “drunken honeycombs”; nuclear
grooves and nuclear membrane irregularities [41]. If these
features are not speciﬁcally sought, a false negative diagnosis
may be rendered.
(2) Intraductal papillary mucinous neoplasm (IPMN):
a 68-year-old female with history of acute pancreatitis of
unclear etiology and associated large pancreatic tail pseu-
docyst was referred for EUS evaluation and possible endo-
scopic drainage of the pseudocyst. EUS showed a 13mm
by 10mm irregular anechoic cystic lesion with hypoechoic
solid component within the tail of pancreas (suspicious for
cystic neoplasm). It was communicating with the main PD.
The PD was itself dilated upstream of this lesion and was
leadingintoalargeanechoicpseudocyst(Figure 8).OneFNA
passwasdoneofthecystic-solidlesionusing22-gaugeneedle
via transgastric approach. The specimen was analyzed by
onsite cytopathologist for adequate cellularity.
This case was a classic example with thick viscid mucin
that did not spread easily nor air-dry readily. Microscopy
revealed classic papillary fronds and numerous macrophages
in a mucinous background (Figure 9). The diagnosis of
IPMN is made based on the characteristic EUS ﬁndings
and cytological features of viscid mucin, macrophages, and
epithelium arranged in ﬁnger like papillae [42]. However,
in addition, the diagnosis of in situ or invasive malignancy
within the IPMN has to be evaluated separately, applying the
usual criteria for malignancy. A note of caution should be
added to the report that, even if no features of malignancyPathology Research International 5
(a) (b) (c)
Figure 6: Pancreatic ductal adenocarcinoma, poorly diﬀerentiated: three-dimensional clusters in (a) Diﬀ-Quik stain at 200x; (b)
Papanicolaou’s stain at 200x; (c) mitosis and hyperchromatic nuclei in cell block, H&E at 200x.
(a) (b) (c)
Figure 7: Pancreatic ductal adenocarcinoma, well-diﬀerentiated: (a) normal pancreatic ductal epithelium, Papanicolaou stain at 400x;
(b) nuclear membrane irregularities, Papanicolaou stain at 600x; (c) well-diﬀerentiated adenocarcinoma with “drunken honeycombs,”
Papanicolaou stain at 400x.
are present in the current aspirate smears, the lesion may
still harbor malignancy in unsampled areas and, therefore,
should be treated surgically.
(3) Pancreatic neuroendocrine tumor: a 48-year-old gen-
tleman was admitted with recent onset headaches and hyper-
tensive urgency. MRI abdomen with and without contrast
showedahypervascular19mmby9mmpancreaticbody/tail
solid lesion. EUS showed an 18.9mm by 9.6mm hypoechoic
mass with anechoic microcystic (most likely necrotic) com-
ponents in body/tail of the pancreas (Figure 10). Three FNA
passes were obtained via transgastric approach. The spec-
imen was analyzed by onsite cytopathologist for adequate
cellularity.
Pancreatic neuroendocrine tumors (NETs) have a variety
of appearances. They can mimic normal pancreatic acinar
parenchyma (Figure 11(a)), a gland forming adenocarci-
noma, an acinar cell carcinoma, or even a plasmacytoma
[43]. Only a small percentage show the classic “salt and
pepper” nuclear detail on alcohol ﬁxed smears and H&E
of cell block. In fact, a single prominent nucleolus is not6 Pathology Research International
(a) (b)
Figure 8: Intraductal papillary mucinous neoplasm (IPMN). (a) An irregular anechoic cystic lesion with hypoechoic solid component was
noted within the tail of pancreas (suspicious for cystic neoplasm). It was communicating with the main PD. (b) The PD was itself dilated
upstream of this lesion and was leading into a large anechoic pseudocyst.
an uncommon ﬁnding. On air-dried Romanowsky-stained
smears, the nuclear details are not as helpful as in alcohol
ﬁxed preparations. The key to a successful diagnosis is
to keep this possibility in the diﬀerential diagnosis and
obtain adequate material in cell block to do the relevant
immunoperoxidase stains for neuroendocrine markers, such
as chromogranin and synaptophysin (Figures 11(e) and
11(g)). Synaptophysin is more sensitive than chromogranin,
but less speciﬁc. A quirky detail to be aware of is that gas-
trointestinal neuroendocrine tumors, including pancreatic
NET, may occasionally be cytokeratin AE1:AE3 negative. It
is therefore important to include Cam 5.2, which is more
reliably positive. As of now, it is not a requirement to do
a Ki67 on the cell block for World Health Organization
(WHO) grading based on proliferative index, but a mitotic
count should be attempted if there is adequate material
in the cell block [44]. As per the WHO classiﬁcation of
neuroendocrine tumors <2 mitosis/10hpf is classiﬁed as a
neuroendocrine tumor, 2–20 mitosis/10hpf is classiﬁed as
a well-diﬀerentiated neuroendocrine carcinoma, and >20
mitosis/10hpf is a high-grade neuroendocrine carcinoma
[45]. A note of caution: sometimes the aspiration needle
may pick up incidental pancreatic endocrine microadenoma
(<5mm) or islet cell proliferations in pancreatic atrophy.
Under these circumstances it is best to correlate with EUS
for their relevance.
(4) High-grade neuroendocrine carcinoma: a 87-year-
old gentleman status after Billroth II surgery and history
of choledocholithiasis with multiple ERCP procedures in
the past presented with a new onset of biliary obstruction.
CT abdomen showed multiple liver lesions and retroperi-
toneal/portal lymphadenopathy suspicious for malignancy.
EUS showed a 29mm by 27mm pancreatic body hypoechoic
and homogenous solid lesion (Figure 12). Two FNAs passed
were done via transgastric approach. The specimen was
analyzed by onsite cytopathologist for adequate cellularity.
Celiac lymphadenopathy and multiple liver lesions were also
noted, consistent with metastases.
Immediate onsite evaluation with Diﬀ-Quik revealed
abundant cellularity and necrosis with closely packed tumor
cells that could be described generically as a “small, blue,
round cell tumor” (Figure 13). The combination of nuclear
molding, nuclear streaking artifact, mitosis, single-cell ne-
crosis, polar cytokeratin staining, and positive neuroendo-
crine markers is diagnostic of a high-grade neuroendocrine
carcinoma. The diﬀerential diagnosis during an onsite eval-
uation of these lesions includes a high-grade lymphoma.
Immunoperoxidase stains, preferably on a cell block, help to
sort out these two entities by a binary algorithm. Lymphoma
is LCA+/CK− while high-grade neuroendocrine carcinoma
is LCA−/CK+. Since high-grade neuroendocrine carcinoma
occurs rarely in the pancreas, a metastasis from a lung
primary should be ruled out. Clinical and chest CT ﬁnd-
ings are more important in establishing a metastasis than
immunohistochemistry, because TTF1 does not reliably dif-
ferentiate the two primaries as TTF1 may be positive in
extrapulmonary small cell carcinoma [46]. As mentioned
earlier, per WHO guidelines, a high-grade neuroendocrine
carcinoma of pancreas would require a mitotic count >20/10
high power ﬁeld (hpf) or a Ki-67 index >20%.
(5)Acinarcellcarcinoma:a47-year-oldfemalewithprior
history of cholecystectomy presented with epigastric pain.
CT abdomen showed a 21mm distal pancreatic body cystic
lesion. EUS showed a 25mm by 23mm hypoechoic solid
lesion with few anechoic cystic areas (most likely necrosis)
in distal pancreatic body (Figure 14). Five passes were donePathology Research International 7
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(d) (e)
Figure 9: Intraductal papillary mucinous neoplasm (IPMN): Muciphages in a necrotic and mucinous background in (a) Papanicolaou stain
at 400x; (b) Diﬀ-Quik stain at 200x; Papillary fronds in (c) Papanicolaou stain at 100x; (d) cell block H&E at 200x; (e) mitosis and cytologic
atypia, cell block H&E at 400x.
(a) (b)
Figure 10: Pancreatic neuroendocrine tumor. (a) EUS showed an 18.9mm by 9.6mm hypoechoic solid mass with anechoic microcystic
(most likely necrotic) components in body/tail of the pancreas. (b) An FNA needle is passed into the solid component via transgastric
approach.8 Pathology Research International
(a) (b) (c)
(d) (e) (f)
(g)
Figure 11: Pancreatic neuroendocrine tumor: (a) normal pancreatic acini, Diﬀ-Quik stain at 400x; (b) cohesive 3-dimensional cluster
in Diﬀ-Quik stain at 200x; (c) discohesive cells with salt and pepper chromatin and rare pinpoint nucleolus in cell block H&E at 400x;
Immunohistochemical proﬁle of the tumor: (d) cytokeratin AE1/AE3 highlights residual ductal epithelium but not the tumor, at 100x; (e)
synaptophysin, strong and diﬀuse positivity, at 400x; (f) positive cytokeratin Cam 5.2 at 200x; (g) positive chromogranin at 400x.
using 22- and 25-gauge needles via transgastric approach.
The specimen was analyzed by onsite cytopathologist for
adequate cellularity.
These tumors tend to be extremely cellular and dyscohe-
siveonaspiratesmears(Figure 15).Typicallytheyhaveabun-
dant cytoplasm and a prominent nucleolus, evident even on
Diﬀ-Quik-stained aspirate smears. Arriving at the correct
ﬁnal diagnosis is only possible after establishing the pres-
ence of zymogen granules by immunohistochemical stains
for trypsin. Acinar cell carcinoma may mimic pancreatic
neuroendocrine tumors on cytomorphology and immun-
ohistochemistry because they may occasionally stain with
neuroendocrinemarkers[47].Inasmallsamplesuchasacell
block preparation, it is often diﬃcult to prove its true lineage
and may be erroneously diagnosed as a neuroendocrine
tumor.
(6) Autoimmune pancreatitis: a 44-year-old gentleman
with new onset diabetes mellitus presented with obstructive
jaundice and weight loss. ERCP showed common hepatic
biliary stricture. Brushings were negative for malignancy. A
plastic biliary stent was placed. CT abdomen showed mild
intrahepatic biliary dilatation, stent in place, but no obvious
mass lesion. EUS was then performed. The pancreas was
diﬀusely enlarged lobulated, and hypoechoic in appearancePathology Research International 9
(a) (b)
Figure 12: High-grade neuroendocrine carcinoma. (a) EUS showed a 29mm by 27mm pancreatic body hypoechoic and homogenous solid
lesion. (b) Multiple solid liver lesions were also noted, consistent with metastases.
(a) (b) (c)
(d) (e)
Figure 13: High-grade neuroendocrine carcinoma: (a) cellular smears with nuclear streaking artifact, Papanicolaou stain at 200x; (b) closely
packed nuclei due to scant cytoplasm, Diﬀ-Quik stain at 200x; (c) and (d) nuclear molding, Papanicolaou and Diﬀ-Quik stains at 400x; (e)
immunoperoxidase stain for cytokeratin Cam 5.2, at 200x.10 Pathology Research International
(a) (b)
Figure 14: Acinar cell carcinoma: EUS showed a 25mm by 23mm hypoechoic solid lesion with few anechoic cystic areas (most likely
necrosis) in distal pancreatic body. (b) An FNA pass is being done using 22-gauge needle via transgastric approach.
(a) (b)
(c) (d)
Figure 15: Acinar cell carcinoma: (a) one cohesive group and scattered bare nuclei, Diﬀ-Quik stain at 400x; (b) abundant cytoplasm and
prominent nucleoli, Diﬀ-Quik stain at 600x, (c) prominent nucleoli, Papanicolaou stain at 400x; (d) discohesive cells in cell block H&E at
400x.
with coarse echogenic foci. The main PD was small in
size. The proximal superior mesenteric vein (SMV) was
encased, and partially obstructed with portal collaterals
(Figure 16). Four passes were done of the pancreatic neck
with 19-gauge Quick core needle via transgastric approach.
After conﬁrmation of adequate cellularity, the specimen was
submitted for cytologic and histologic analyses.
Aspirate smears from sclerotic areas in autoimmune
pancreatitis (AIP) may yield no cells; conversely, identify-
ing ductal epithelium during onsite evaluation does notPathology Research International 11
(a) (b)
Figure 16: Autoimmune pancreatitis: EUS showed the entire pancreas to be diﬀusely enlarged, lobulated, and hypoechoic in appearance
with coarse echogenic foci. The main PD was small in size. (a) and (b) showed the changes in body and head of pancreas, respectively. The
proximal SMV (superior mesenteric vein) was encased and partially obstructed.
(a) (b) (c)
Figure 17: Autoimmune pancreatitis: sclerotic parenchyma compared to an intact acinar parenchyma, H&E cell block at 100x (a), inﬁltrated
by inﬂammatory cells, H&E cell block at 100x (b), consisting predominantly of lymphocytes and rare eosinophils, H&E cell block at 100x
(c).
guarantee diagnostic tissue in the cell block. Therefore, there
is only a limited role for onsite evaluation if this diagnosis
is already radiologically and serologically (elevated serum
IgG4) established. Typically, the role for cytopathologist
during the EUS-FNA procedure in patients with AIP is
to rule out a pancreatic malignancy in a mass lesion. For
suspected AIP lesions, instead of an FNA, a core biopsy with
cutting needle is preferable [48] for documenting sclerosis,
pancreatic atrophy, and lymphoplasmacytic inﬂammation
in the sclerotic areas, by means of a cell block (Figure 17).
Inﬂammation is usually patchy and includes predominantly
lymphocytes [49]. If suﬃcient numbers of plasma cells are
present, IgG4 stain may be attempted on the cell block by
immunohistochemistry.
(7) Solid pseudopapillary tumor: a 43-year-old female
with no signiﬁcant past medical history presented with
abdominal pain. CT abdomen showed a 3cm cystic lesion
in the head of pancreas. EUS showed a 36mm anechoic
irregular lesion with a hypoechoic thick irregular rim and
a solid polypoid component in the pancreatic head/body12 Pathology Research International
(a) (b)
Figure 18: Solid pseudopapillary tumor. (a) EUS showed a 36mm anechoic cystic lesion with a hypoechoic thick irregular rim and a solid
polypoid component in the pancreatic head/body junction. (b) The cystic and solid components were separately FNA using a 19-gauge
needle via transgastric approach.
junction (Figure 18). The cystic and solid components were
separately aspirated using a 19-gauge needle via transgastric
approach. The specimen adequacy was conﬁrmed by an
onsite cytopathologist.
Onsite evaluation revealed markedly cellular aspirate
smears with the cells arrayed along elongate papillary struc-
t u r e sw i t hc e n t r a lﬁ b r o v a s c u l a rc o r e s( Figure 19). Uniformly
bland, dyscohesive cells were scattered between the papillae.
There was no mucin or macrophages in the background.
These two key features (papillae and bland dyscohesive
cells) were the clues to a spot diagnosis of solid and cystic
pseudopapillary tumor of pancreas [50]. Immunohisto-
chemical proﬁle of this tumor is interesting: mostly negative
for cytokeratin, positive for vimentin and CD10 and nuclear
staining for beta catenin [51].
(8) Metastatic lung cancer An 80-year-old female with
historyofbilaterallungadenocarcinoma,surgicallobectomy,
chemotherapy, and radiation in the past presented with
new onset jaundice. CT abdomen showed a large 38mm
by 31mm mass located in the peripancreatic area that was
causing distal CBD stenosis. PET scan showed an increasing
hypermetabolicfocusinthesamearea,suggestiveofneoplas-
tic process. EUS showed a 37mm by 30mm well-deﬁned,
hypoechoic, and heterogeneous peripancreatic mass at the
level of pancreatic head causing distal CBD stenosis (Figure
20). Two FNA passes were done using 25-gauge needle via
transduodenal approach. The specimen was analyzed by
onsite cytopathologist for adequate cellularity.
The composite on Figure 21 shows adequate atypical
clusters on immediate evaluation. It does not appear dif-
ferent from a pancreatic ductal adenocarcinoma. How-
ever, on immunohistochemistry, the tumor was CK7+/
TTF1+/CK20−. This immunoproﬁle is consistent with the
lung primary. A typical pancreatic primary would be CK7+/
TTF1−/CK20+. Clinical history and cell block for immuno-
histochemistry are essential in arriving at the right diagnosis.
(9)Metastaticrenalcellcancer:a73-year-oldwomanwas
found to have multiple peripancreatic masses, left adrenal
mass, and a left lower pole kidney mass on imaging studies.
EUS showed multiple conﬂuent, well-circumscribed hypoe-
choic, spherical masses, measuring up to 40mm, in the
peripancreatic (head) area compressing distal CBD. Multiple
anechoic areas were noted within these mass, representing
necroses (Figure 22). A single FNA pass was done using a 19-
gauge needle via transduodenal approach. A 31mm hypoe-
choic, well-circumscribed mass was noted in left adrenal.
Its appearance was similar to other masses imaged. One
FNA pass was done using 22-gauge needle via transgastric
approach and submitted for cell block only. The peripancre-
aticmasswasanalyzedbyonsitecytopathologistforadequate
cellularity.
Onsite evaluation of the peripancreatic mass showed
an extremely cellular aspirate on Diﬀ Quick stain and was
deemed adequate for evaluation. The clear cell morphology
of the metastatic tumor is best appreciated on routine H&E
stain of the cell block (Figure 23), least evident on air-
dried smears for onsite evaluation, moderately so on alcohol
ﬁxed, Papanicolaou-stained smears. Cell blocks from both
lesions (peripancreatic and left adrenal) showed identical
morphology with clear cells. Immunoperoxidase stains are
mandatory to diﬀerentiate the following: normal left adrenal
cortical parenchyma/adrenal cortical adenoma versus a left
clear cell renal carcinoma (RCC) in the upper pole. Normal
adrenal cortical parenchyma cannot be distinguished from
an adrenal cortical adenoma by immunoperoxidase stains
but they can both be distinguished from an RCC. Synapto-
physin, Melan 1, and inhibin are positive in adrenal cortical
cells while CD10, vimentin, and RCC antigen highlight RCCPathology Research International 13
(a) (b) (c)
(d) (e) (f)
Figure 19: Solid pseudopapillary tumor: (a) slender pseudopapillary structures, Papanicolaou stain at 200x; (b) central ﬁbrovascular cores,
Diﬀ-Quik stain at 400x; (c) cell block, H&E at 200x; immunoperoxidase stains (d) positive vimentin, 200x; (e) positive CD10, 400x; (f).
negative cytokeratin Cam 5.2, 200x.
(a) (b)
Figure 20: Metastatic lung cancer. (a) EUS showed a 37mm by 30mm well-deﬁned, hypoechoic, and heterogeneous peripancreatic solid
mass at the level of pancreatic head causing distal CBD stenosis. (b) Two FNA passes were done using 25-gauge needle via transduodenal
approach.14 Pathology Research International
(a) (b)
(c) (d)
Figure 21: Lung metastasis to pancreas: (a) tumor cell clusters, Diﬀ-Quik stain at 200x; (b) strips of tumor epithelium, H&E cell block at
200x; (c) cytoplasmic staining of cytokeratin CK7, immunoperoxidase stain, 400x; (d) nuclear staining of TTF1, immunoperoxidase stain,
200x.
(a) (b)
Figure 22: Renal metastasis to pancreas. (a) EUS showed multiple conﬂuent, well-circumscribed hypoechoic, spherical masses measuring
up to 40mm in the peripancreatic (head) area compressing distal CBD. Multiple anechoic areas of necrosis were seen inside the lesions. (b)
A single FNA pass was done using a 19-gauge needle via transduodenal approach.Pathology Research International 15
(a) (b) (c)
(d) (e) (f)
Figure 23: Renal metastasis to pancreas: (a) and (b) abundant, bubbly cytoplasm, Diﬀ-Quik stain at 200x and 400x; (c) clear cytoplasm,
outlined by sharp cell membrane, cell block H&E at 200x; (d) positive CD10 immunoperoxidase stain, at 400x; (e) negative cytokeratin CK7,
at 400x; (f) positive vimentin immunoperoxidase stain, at 400x.
and do not crossreact with adrenal cortex [52]. Based on the
immunohistochemical proﬁle, both masses were diagnosed
as metastatic renal cell carcinoma to peripancreatic tissue
and left adrenal.
7. Conclusion
In summary, endoscopic ultrasound is the most sensitive
imaging modality for solid pancreatic lesions. It is an
outpatient safe procedure, with high accuracy of 78–94%
for T (local tumor) stage and 64–82% for N (lymph node)
stage. The speciﬁcity is low (about 75%), but can be
increasedto100%withanaccuracyof95%withtheaddition
of ﬁne needle aspiration. The diagnostic yield of EUS-
FNA for solid pancreatic lesion is 86.8–98.5% for cytologic
and 68.9–89% for histologic examinations, while 65–100%
for lymph nodes. Factors related to either endoscopist or
cytopathologist aﬀect the diagnostic yield of EUS-FNA. A
close interaction with cytopathologist is vital in improving
the diagnostic yield. The ﬁnal diagnosis is based upon
correlation of clinical, EUS, and cytologic features.
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